orvida
1 known investors
Find your way into orvida
56 people in our graph share verified history with the orvida team — schools, employers, funds. One of them is your warm intro.
Oren Kaplanunlockedknows David Aviezer · together at Bar-Ilan University (overlapped)
knows the team · via Protalix Biotherapiutics
×10knows the team · via Weizmann Institute of Science
Orvida Pharma develops pharmaceuticals for rare genetic skin diseases and orphan indications, with expertise spanning drug development from early discovery through FDA and EMA regulatory approval.
Founders & leadership
DA
David AviezerinCEODavid Aviezer holds a Ph.D. in Biochemistry & Molecular Biology from the Weizmann Institute of Science and an MBA from Bar Ilan University. He spent over 25 years in biotechnology, including 12 years as President & CEO of Protalix Biotherapeutics, where he oversaw FDA approval of Elelyso for Gaucher Disease and a NYSE listing, and now leads Orvida Pharma in developing therapeutics for rare genetic skin diseases.
LB
Liora BraimanPhD
Investors · 1
Frequently asked questions
- What does orvida do?
- Orvida Pharma develops pharmaceuticals for rare genetic skin diseases and orphan indications, with expertise spanning drug development from early discovery through FDA and EMA regulatory approval.
- Who are orvida's investors?
- orvida's investors include BRM Capital.